Cinedigm Corp. (CIDM) Forms $1.33 Double Bottom; Ardsley Advisory Partners Has Raised Neurocrine Biosciences (NBIX) Holding By $5.64 Million

Cinedigm Corp. (CIDM) formed double bottom with $1.29 target or 3.00% below today’s $1.33 share price. Cinedigm Corp. (CIDM) has $46.48 million valuation. The stock increased 0.76% or $0.01 during the last trading session, reaching $1.33. About 12,305 shares traded. Cinedigm Corp. (NASDAQ:CIDM) has risen 29.23% since March 13, 2017 and is uptrending. It has outperformed by 12.53% the S&P500.

Ardsley Advisory Partners increased Neurocrine Biosciences Inc (NBIX) stake by 1850% reported in 2017Q3 SEC filing. Ardsley Advisory Partners acquired 92,500 shares as Neurocrine Biosciences Inc (NBIX)’s stock rose 19.84%. The Ardsley Advisory Partners holds 97,500 shares with $5.98 million value, up from 5,000 last quarter. Neurocrine Biosciences Inc now has $8.09B valuation. The stock decreased 1.99% or $1.84 during the last trading session, reaching $90.59. About 484,320 shares traded. Neurocrine Biosciences, Inc. (NASDAQ:NBIX) has risen 12.51% since March 13, 2017 and is uptrending. It has underperformed by 4.19% the S&P500.

Among 13 analysts covering Neurocrine Biosci (NASDAQ:NBIX), 13 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Neurocrine Biosci had 50 analyst reports since August 18, 2015 according to SRatingsIntel. The firm earned “Overweight” rating on Thursday, November 2 by Barclays Capital. The firm has “Buy” rating given on Monday, October 23 by Robert W. Baird. JP Morgan maintained the shares of NBIX in report on Wednesday, February 14 with “Overweight” rating. Needham maintained the shares of NBIX in report on Friday, September 15 with “Buy” rating. The firm has “Buy” rating by Oppenheimer given on Thursday, September 7. The stock has “Buy” rating by H.C. Wainwright on Wednesday, February 14. The firm has “Buy” rating by Oppenheimer given on Thursday, February 22. On Monday, October 12 the stock rating was maintained by Leerink Swann with “Outperform”. Oppenheimer maintained it with “Buy” rating and $7000 target in Wednesday, July 5 report. As per Monday, June 26, the company rating was maintained by Jefferies.

Ardsley Advisory Partners decreased Celgene Corp (NASDAQ:CELG) stake by 126,000 shares to 10,000 valued at $1.46 million in 2017Q3. It also reduced Parsley Energy Inc (NYSE:PE) stake by 25,000 shares and now owns 600,000 shares. Pattern Energy Group Inc (NASDAQ:PEGI) was reduced too.

Since September 29, 2017, it had 0 buys, and 24 insider sales for $31.24 million activity. Grigoriadis Dimitri E. also sold $169,997 worth of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) on Monday, February 5. $227,494 worth of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) shares were sold by Lippoldt Darin. Bozigian Haig P. also sold $128,575 worth of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) shares. 5,000 shares were sold by LYONS GARY A, worth $415,380. Shares for $79,863 were sold by Lloyd-Smith Malcolm. GORMAN KEVIN CHARLES had sold 3,750 shares worth $295,820 on Tuesday, January 16. Another trade for 1,750 shares valued at $138,499 was made by OBrien Christopher Flint on Tuesday, January 16.

Investors sentiment decreased to 1.31 in Q3 2017. Its down 0.35, from 1.66 in 2017Q2. It is negative, as 22 investors sold NBIX shares while 45 reduced holdings. 32 funds opened positions while 79 raised stakes. 92.69 million shares or 0.83% more from 91.92 million shares in 2017Q2 were reported. Birchview Capital Lp has invested 1.66% of its portfolio in Neurocrine Biosciences, Inc. (NASDAQ:NBIX). Rhumbline Advisers has 105,561 shares for 0.01% of their portfolio. Next Group Inc reported 275 shares. Wells Fargo Mn, California-based fund reported 945,368 shares. 232,602 were reported by Sectoral Asset. Quantitative Invest Management Limited Liability has 0.05% invested in Neurocrine Biosciences, Inc. (NASDAQ:NBIX). Dupont Corp holds 72,497 shares or 0.1% of its portfolio. Nomura Asset Mngmt Ltd owns 14,611 shares. 339,440 are owned by Artisan Partners Partnership. Rock Springs Mngmt Ltd Partnership reported 440,000 shares. D E Shaw & stated it has 0% in Neurocrine Biosciences, Inc. (NASDAQ:NBIX). Moreover, Pictet Asset Mngmt Limited has 0.23% invested in Neurocrine Biosciences, Inc. (NASDAQ:NBIX). Jpmorgan Chase Company reported 0.01% stake. Bnp Paribas Asset Management Sa holds 522,801 shares. Schwab Charles Invest Inc reported 383,688 shares or 0.02% of all its holdings.